KEGG DRUG

Search results

No.	薬物名（臨床試験情報から抽出）	DrugBank	KEGG DRUG	KEGG GENES	KEGG PATHWAY	指定難病告示番号
1	J01GB01	-	-	-	-	1件: 299 💬
2	J05A F01	-	-	-	-	1件: 135 💬
3	J05AG04	-	-	-	-	1件: 18 💬
4	J07AH07	-	-	-	-	1件: 14 💬
5	J1081	-	-	-	-	1件: 56 💬
6	J695	-	-	-	-	1件: 96 💬
7	J695, BSF 415977 (formerly LU415977), WAY-165772, A-796874.0	-	-	-	-	1件: 96 💬
8	JAK 3	-	-	-	-	1件: 46 💬
9	JAK 3 Ritlecitinib	-	-	-	-	1件: 46 💬
10	JAK inhibitor	-	-	-	-	2件: 46, 50 💬
11	JAK1 / JAK2 Inhibitor	-	-	-	-	1件: 46 💬
12	JAK1 / JAK2 Inhibtor	-	-	-	-	1件: 46 💬
13	JAKi	-	-	-	-	1件: 46 💬
14	Jaktinib Dihydrochloride Monohydrate 50mg BID and Mimic tablets of jakitinib hydrochloride 75mg BID and Acetylcysteine Effervescent Tablets	1件: Acetylcysteine	1件: Acetylcysteine 💬	-	-	1件: 85 💬
15	Jaktinib Dihydrochloride Monohydrate 75mg BID and Mimic tablets of jakitinib hydrochloride 50mg BID and Acetylcysteine Effervescent Tablets	1件: Acetylcysteine	1件: Acetylcysteine 💬	-	-	1件: 85 💬
16	Jaktinib Hydrochloride Tablets	-	-	-	-	1件: 271 💬
17	Janus Kinase Inhibitor	-	-	-	-	2件: 46, 97 💬
18	Jardiance	1件: Empagliflozin	1件: Empagliflozin 💬	1件: SLC5A2 💬	-	1件: 65 💬
19	JBT-101	-	-	-	-	4件: 49, 50, 51, 299 💬
20	JBT-101 (lenabasum)	-	-	-	-	1件: 299 💬
21	JBT101	-	-	-	-	1件: 299 💬
22	Jevity 1.0	-	-	-	-	1件: 2 💬
23	Jevity 1.5	-	-	-	-	1件: 2 💬
24	JHL1101	-	-	-	-	1件: 46 💬
25	Jianpixiaozhong particles and Wuse Dietotherapy	-	-	-	-	1件: 222 💬
26	Jinarc	1件: Tolvaptan	1件: Tolvaptan 💬	1件: AVPR2 💬	3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬	1件: 67 💬
27	JINARC - 15 MG +45 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28X15 MG + 28 X 45 MG)	1件: Tolvaptan	1件: Tolvaptan 💬	1件: AVPR2 💬	3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬	1件: 67 💬
28	JINARC - 15 MG - COMPRESSA - USO ORALE - BLISTER (ALU/PVC) - 28 COMPRESSE	1件: Tolvaptan	1件: Tolvaptan 💬	1件: AVPR2 💬	3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬	1件: 67 💬
29	JINARC - 30 MG + 60 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28 X 30 MG + 28 X 60 MG)	1件: Tolvaptan	1件: Tolvaptan 💬	1件: AVPR2 💬	3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬	1件: 67 💬
30	JINARC - 30 MG +90 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28 X 30 MG + 28 X 90 MG)	1件: Tolvaptan	1件: Tolvaptan 💬	1件: AVPR2 💬	3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬	1件: 67 💬
31	JINARC - 30 MG - COMPRESSA - USO ORALE - BLISTER (ALU/PVC) - 28 COMPRESSE	1件: Tolvaptan	1件: Tolvaptan 💬	1件: AVPR2 💬	3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬	1件: 67 💬
32	Jinarc - Tolvaptan tablets	1件: Tolvaptan	1件: Tolvaptan 💬	1件: AVPR2 💬	3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬	1件: 67 💬
33	Jinarc 15 mg tablets, Jinarc 45 mg tablets	1件: Tolvaptan	1件: Tolvaptan 💬	1件: AVPR2 💬	3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬	1件: 67 💬
34	Jinarc 30 mg Tablet	1件: Tolvaptan	1件: Tolvaptan 💬	1件: AVPR2 💬	3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬	1件: 67 💬
35	Jinarc 30 mg tablets, 90 mg tablets	1件: Tolvaptan	1件: Tolvaptan 💬	1件: AVPR2 💬	3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬	1件: 67 💬
36	Jinarc 30 mg tablets, Jinarc 60 mg tablets	1件: Tolvaptan	1件: Tolvaptan 💬	1件: AVPR2 💬	3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬	1件: 67 💬
37	Jinarc® 15mg Tablet	1件: Tolvaptan	1件: Tolvaptan 💬	1件: AVPR2 💬	3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬	1件: 67 💬
38	Jinarc® 30 Tablet	1件: Tolvaptan	1件: Tolvaptan 💬	1件: AVPR2 💬	3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬	1件: 67 💬
39	Jintropin AQ	-	-	-	-	1件: 78 💬
40	JKB-122	-	-	-	-	1件: 95 💬
41	JKB-122 in capsule or tablet form	-	-	-	-	1件: 95 💬
42	JM	-	-	-	-	2件: 6, 13 💬
43	JM-010	-	-	-	-	1件: 6 💬
44	JM-4	-	-	-	-	1件: 13 💬
45	JNJ 38518168	-	-	-	-	1件: 46 💬
46	JnJ 54767414	-	-	-	-	1件: 28 💬
47	JNJ-16240159-AAC	-	-	-	-	1件: 46 💬
48	JNJ-31001074	-	-	-	-	1件: 6 💬
49	JNJ-38518168	-	-	-	-	1件: 46 💬
50	JNJ-38518168 (10 mg)	-	-	-	-	1件: 46 💬
51	JNJ-38518168 (3 mg)	-	-	-	-	1件: 46 💬
52	JNJ-38518168 (30 mg)	-	-	-	-	1件: 46 💬
53	JNJ-38518168 / MTX	-	-	-	-	1件: 46 💬
54	JNJ-38518168 50-mg Over Encapsulated Tablet	-	-	-	-	1件: 46 💬
55	JNJ-38518168-AEK - Over Encapsulated Tablet - 50 mg	-	-	-	-	1件: 46 💬
56	JNJ-38518168-ZBQ	-	-	-	-	1件: 46 💬
57	JNJ-38518168-ZBQ - film-coated tablet - 10 mg	-	-	-	-	1件: 46 💬
58	JNJ-38518168-ZBQ - film-coated tablet - 10mg	-	-	-	-	1件: 46 💬
59	JNJ-38518168-ZBQ - film-coated tablet - 3 mg	-	-	-	-	1件: 46 💬
60	JNJ-38518168-ZBQ - film-coated tablet - 30 mg	-	-	-	-	1件: 46 💬
61	JNJ-38518168-ZBQ - film-coated tablet - 30mg	-	-	-	-	1件: 46 💬
62	JNJ-38518168-ZBQ - film-coated tablet - 3mg	-	-	-	-	1件: 46 💬
63	JNJ-39039039	-	-	-	-	1件: 210 💬
64	JNJ-39758979	-	-	-	-	1件: 46 💬
65	JNJ-39758979 (10 mg)	-	-	-	-	1件: 46 💬
66	JNJ-39758979 (100 mg)	-	-	-	-	1件: 46 💬
67	JNJ-39758979 (30 mg)	-	-	-	-	1件: 46 💬
68	JNJ-39758979 (300 mg)	-	-	-	-	1件: 46 💬
69	JNJ-39758979 / MTX	-	-	-	-	1件: 46 💬
70	JNJ-39758979-AAC - enteric coated tablet - 10 mg	-	-	-	-	1件: 46 💬
71	JNJ-39758979-AAC - enteric coated tablet - 100 mg	-	-	-	-	1件: 46 💬
72	JNJ-39758979-AAC - enteric coated tablet - 30 mg	-	-	-	-	1件: 46 💬
73	JNJ-40346527	1件: JNJ-40346527	-	-	-	2件: 46, 96 💬
74	JNJ-40346527-AAC	1件: JNJ-40346527	-	-	-	1件: 96 💬
75	JNJ-40346527-AAC - capsule - 50 mg	1件: JNJ-40346527	-	-	-	1件: 46 💬
76	JNJ-42160443	-	-	-	-	1件: 226 💬
77	JNJ-54767414	-	-	-	-	2件: 28, 49 💬
78	JNJ-54781532 150 mg once daily	-	-	-	-	1件: 97 💬
79	JNJ-54781532 25 mg once daily	-	-	-	-	1件: 97 💬
80	JNJ-54781532 75 mg once daily	-	-	-	-	1件: 97 💬
81	JNJ-54781532 75 mg twice daily	-	-	-	-	1件: 97 💬
82	JNJ-54781532-AAD-10 mg	-	-	-	-	1件: 97 💬
83	JNJ-54781532-AAD-30 mg	-	-	-	-	1件: 97 💬
84	JNJ-54781532-AAD-5 mg	-	-	-	-	1件: 97 💬
85	JNJ-55920839	-	-	-	-	1件: 49 💬
86	JNJ-56022473	-	-	-	-	1件: 49 💬
87	JNJ-64304500	-	-	-	-	1件: 96 💬
88	JNJ-64304500-AAA	-	-	-	-	1件: 96 💬
89	JNJ-64841829	-	-	-	-	1件: 97 💬
90	JNJ-64841842	-	-	-	-	1件: 97 💬
91	JNJ-64841855	-	-	-	-	1件: 97 💬
92	JNJ-64841894	-	-	-	-	1件: 97 💬
93	JNJ-64841907	-	-	-	-	1件: 97 💬
94	JNJ-64841920	-	-	-	-	1件: 97 💬
95	JNJ-64841933	-	-	-	-	1件: 97 💬
96	JNJ-64841946	-	-	-	-	1件: 97 💬
97	JNJ-66525433	-	-	-	-	1件: 97 💬
98	JNJ-67484703	-	-	-	-	1件: 46 💬
99	JNJ-67864238	-	-	-	-	1件: 96 💬
100	JNJ-67896049	-	-	-	-	1件: 86 💬
101	JNJ-67896049 (ACT-293987)	-	-	-	-	1件: 86 💬
102	JNJ-67896062 / ACT-064992	-	-	-	-	2件: 86, 88 💬
103	JNJ-67896062/ ACT-064992	-	-	-	-	2件: 86, 88 💬
104	JNJ-67896062/ACT-064922	-	-	-	-	1件: 86 💬
105	JNJ-67896153/ACT-128800	-	-	-	-	1件: 13 💬
106	JNJ-72537634	-	-	-	-	1件: 97 💬
107	JNJ-78934804	-	-	-	-	2件: 96, 97 💬
108	JNJ-80202135	-	-	-	-	4件: 11, 46, 49, 53 💬
109	JNJ31-31001074	-	-	-	-	1件: 6 💬
110	Joint puncture	-	-	-	-	1件: 107 💬
111	Jojoba oil	1件: Jojoba oil	-	-	-	1件: 36 💬
112	Jojoba oil with broccoli sprout extract	2件: Broccoli, Jojoba oil	-	-	-	1件: 36 💬
113	Jorveza	1件: Budesonide	1件: Budesonide 💬	1件: NR3C1 💬	1件: Neuroactive ligand-receptor interaction 💬	1件: 98 💬
114	Jorveza 0.5 mg compresse orodispersibili	1件: Budesonide	1件: Budesonide 💬	1件: NR3C1 💬	1件: Neuroactive ligand-receptor interaction 💬	1件: 98 💬
115	Jorveza 0.5 mg orodispersible tablets	1件: Budesonide	1件: Budesonide 💬	1件: NR3C1 💬	1件: Neuroactive ligand-receptor interaction 💬	1件: 98 💬
116	Jorveza 1 mg compresse orodispersibili	1件: Budesonide	1件: Budesonide 💬	1件: NR3C1 💬	1件: Neuroactive ligand-receptor interaction 💬	1件: 98 💬
117	Jorveza 1 mg orodispersible tablets	1件: Budesonide	1件: Budesonide 💬	1件: NR3C1 💬	1件: Neuroactive ligand-receptor interaction 💬	1件: 98 💬
118	JP 1730	-	-	-	-	1件: 6 💬
119	JP-1730/F01	-	-	-	-	2件: 6, 17 💬
120	JP-1730/F02	-	-	-	-	2件: 6, 17 💬
121	JP-1730/F03	-	-	-	-	2件: 6, 17 💬
122	JR-141	-	-	-	-	1件: 19 💬
123	JR-141 or Idursulfase	1件: Idursulfase	1件: Idursulfase 💬	1件: IDS 💬	3件: Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬	1件: 19 💬
124	JR-171 (lepunafusp alfa)	-	-	-	-	1件: 19 💬
125	JS002	-	-	-	-	1件: 79 💬
126	JS005	-	-	-	-	1件: 271 💬
127	JSP191	-	-	-	-	2件: 65, 285 💬
128	JTE-051	-	-	-	-	1件: 46 💬
129	JTT-251	-	-	-	-	1件: 86 💬
130	Juanbi pill	-	-	-	-	1件: 46 💬
131	Juvit D3	-	-	-	-	1件: 6 💬
132	Jyseleca	1件: Filgotinib	1件: Filgotinib 💬	1件: JAK1 💬	27件: Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬	1件: 46 💬
133	Jyseleca 100 mg film-coated tablets	1件: Filgotinib	1件: Filgotinib 💬	1件: JAK1 💬	27件: Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬	1件: 46 💬
134	Jyseleca 200 mg film-coated tablets	1件: Filgotinib	1件: Filgotinib 💬	1件: JAK1 💬	27件: Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬	1件: 46 💬
135	JZP-110	-	-	-	-	1件: 6 💬